XCells Biotechnologies USA, Inc. ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent stem ...

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its ...

XCells Biotechnologies USA Inc. has delivered over 500 characterized induced pluripotent stem cell lines as part of a multi-year collaboration with a global biotechnology company.

SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of Good Manufacturing Practices (GMP), cutting-edge, induced pluripotent stem cell (iPSC) technologies, today announced the immediate ...

Market expansion in med derm cross over: Almirall’s Seysara (sarecycline) won NMPA approval for moderate to severe acne (≥9 years), with China commercial launch targeted for 2026 – relevant to ...

Scientists at the Centre for Genomic Regulation (CRG) and other institutions have published details of a treatment that accelerates the production of female induced pluripotent stem cells (iPSCs) from ...

Accelerated Biosciences and Stemmatters are thrilled to announce their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells (“iPSC”) derived from human ...

Findings can be used to accelerate the creation of female stem cell lines in mice and boost efforts in medical research, drug testing, and regenerative therapies Researchers at the Centre for Genomic ...

Avoiding many of the pitfalls associated with conventional iPSC reprogramming methods that can introduce genetic instability, PSXi013 has been reprogrammed using our state-of-the-art, footprint-free ...